Interestingly, a synthetic FFAR3 (GPR41) agonist (AR420626) corrected the movement disorder and neuronal loss in a 6-hydroxydopamine (OHDA, a neurotoxin)-induced PD mouse model163. Here, FFAR3 is linked to movement disorder.